Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Phase 1 data from a new TROP2 targeted Antibody drug conjugate (SHR-A1921, Jiangsu Hengrui Pharmaceuticals) in solid tumors, published in Cancer Cell.
“No significant correlation was found between TROP-2 expression and treatment efficacy” – Pathologists.”
Title: TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
Authors: Jia Zhong, Lin Wu, Zhengbo Song, Nianzeng Xing, Jiujie Cui, Xingya Li, Kailun Fei, Dihong Tang, Qi Dang, Liang Chen, Tianshu Liu, Caigang Liu, Yong Li, Shichuan Zhang, Xinghua Han, Juxiang Xiao, Feng Guo, Min Yan, Huiting Xu, Chunxiu Yuan, Jincai Zhong, Rongrui Liu, Xiujuan Qu, Shikai Wu, Shusuan Jiang, Yan Yang, Panpan Zhang, Hongqian Guo, Ce Wang, Qiushi Xie, Zhifei Lin, Shuni Wang, Jie Wang
Read the Full Article.
More posts featuring Anirban Maitra.
